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More help for patients with less 
severe heart failure
Adding this drug to the medication regimen of 
patients with Class II heart failure can help to reduce 
hospitalization and death rates. 
PRACTICE CHANGER 
Prescribe a mineralocorticoid-receptor an-
tagonist for patients with New York Heart 
Association (NYHA) Class II systolic heart 
failure and an ejection fraction (EF) ≤30%. 
Eplerenone has been found to decrease hos-
pitalizations for heart failure and cardiovas-
cular and all-cause mortality.1 
StREngtH of REcoMMEnDAtion 
A: Based on one high-quality randomized 
controlled trial (RCT).
 
Zannad F, McMurray JJ, Krum H, et al; EMPHASIS-HF Study Group. 
Eplerenone in patients with systolic heart failure and mild symptoms. 
N Engl J Med. 2011;364:11-21. 
ILLUSTRATIVE CASE
a 56-year-old man with a history of systolic 
heart failure and an ef of 30% returns to your 
clinic for routine follow-up. he reports that he 
gets mildly short of breath while mowing the 
lawn, but his condition is stable. he’s already 
taking an angiotensin-converting enzyme in-
hibitor (acei) and a beta-blocker, and his po-
tassium level is 4.8 mmol/l. Should he also be 
taking eplerenone?
Heart failure has reached epidemic proportions in the United States.2-4 Each year, heart failure accounts 
for more than 1 million hospitalizations,3,5 
and millions more are living with the dis-
ease.2 ACEIs and beta-blockers are known 
to decrease hospitalization and mortality for 
these patients. Recent evidence suggests that 
mineralocorticoid-receptor antagonists have 
additional benefits.2,4,6
Benefits for class iii and iV heart failure 
are well established
The Randomized Aldactone Evaluation Study 
(RALES) showed that spironolactone de-
creased all-cause mortality and hospitaliza-
tion for cardiovascular causes in patients with 
Class III and IV heart failure.7 In the Ephesus 
study, the addition of eplerenone to optimal 
therapy reduced morbidity and mortality in 
patients with a myocardial infarction (MI) 
complicated by systolic heart failure.8 These 
studies led to the current guidelines, which 
recommend using a mineralocorticoid- 
receptor antagonist for patients with 
NYHA Class III and IV heart failure, as well 
as patients with acute MI and either left 
ventricular dysfunction or heart failure.2,4,6 
Until recently, however, there was no reason 
to think about using this class of medications 
for patients with less severe disease. 
STUDY SUMMARY
Eplerenone improves outcomes  
for patients with mild symptoms 
The Eplerenone in Mild Patients Hospital-
ization and Survival Study in Heart Failure 
(EMPHASIS-HF)1 was a randomized, double-
blinded trial designed to evaluate the effect 
of eplerenone on patients with less severe 
disease. Eligible patients were older than 
55 years, with Class II heart failure and an 
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EF ≤30% (or >30%-35% with a QRS interval 
>130 ms). Their existing drug regimen had to 
include an ACEI, angiotensin receptor block-
er, or both, as well as a beta-blocker. Patients 
with a potassium level >5.0 mmol/L, acute 
MI, or a low glomerular filtration rate (GFR 
<30 mL/min) were excluded. 
Randomization occurred within 6 
months of hospitalization for a cardiovas-
cular disorder; study participants without a 
recent hospitalization were included if they 
had either a plasma level of B-type natriuret-
ic peptide (BNP) >250 pg/mL or a pro-BNP 
>500 pg/mL for men or >750 pg/mL for wom-
en. A total of 2737 patients were random-
ized to receive either eplerenone 25 mg/d 
(the daily dosage was increased to 50 mg af-
ter 4 weeks if the potassium level remained 
<5 mmol/L) or placebo. Patients with an es-
timated GFR of 30 to 49 mL/min were start-
ed on 25 mg eplerenone every other day; if 
that dose was tolerated, it was increased to 
25 mg/d after 4 weeks.
The primary outcome was a composite 
of death from cardiovascular causes or a first 
hospitalization for heart failure. Secondary 
outcomes included any hospitalization for 
heart failure, all-cause mortality, and cardio-
vascular death. 
Patients were evaluated every 4 months. 
The dose of the eplerenone was decreased if 
the potassium level was 5.5 to 5.9 mmol/L, 
and stopped altogether if potassium was 
>6 mmol/L. Potassium levels were measured 
within 72 hours of a dosage change, and the 
drug restarted if potassium levels returned to 
<5.0 mmol/L.
After 5 months of data collection, 60% of 
patients in the eplerenone group were on the 
higher dosage (50 mg/d), as were 65% of the 
patients receiving placebo. At the conclusion 
of the trial, the study drug had been discon-
tinued in 16% of patients in the eplerenone 
group and 17% of the controls.
The primary outcome (death from a car-
diovascular cause or hospitalization for heart 
failure) occurred in 18% of patients in the 
eplerenone group vs 26% of those on placebo. 
The number needed to treat to prevent one 
primary outcome was estimated to be 19 per 
year of follow-up, and 51 per year of follow-
up to postpone one death. The study was ter-
minated early (after a median follow-up of 21 
months) due to the clear benefits that were 
evident in the eplerenone group. 
WHAT’S NEW?
We have another way to help  
class ii patients
Previously, mineralocorticoid-receptor an-
tagonists were recommended only for care-
fully selected patients—those with a history 
of MI and heart failure, diabetes and heart 
failure, or more severe (Class III or IV) heart 
failure.4,7 This study shows that heart failure 
patients with milder symptoms can benefit 
from eplerenone, as well.
CAVEATS
cost differential means it pays  
to try spironolactone first
Eplerenone is expensive (approximately 
$100 for 30 25-mg tablets at Drugstore.com 
compared with $4 for the same quantity of 
spironolactone at Walmart.com). Because 
eplerenone’s beneficial effects are likely due 
to its action as a mineralocorticoid-receptor 
antagonist, it makes sense to use spironolac-
tone as a first-line agent and reserve eplere-
none for patients who cannot tolerate it. 
Risk of hyperkalemia
Both spironolactone and eplerenone can 
cause hyperkalemia and should not be used 
in patients with a baseline potassium level 
>5.0 mmol/L. Patients who are started on ei-
ther of these medications should have their 
potassium levels checked after 3 days, 7 days, 
and 1 month, then periodically, whenever the 
dosage is changed.4 If the potassium level is 
>5.0 mmol/L, the dose should be decreased 
by 50%—and the drug should be stopped if 
the potassium level is >5.5 mmol/L.1
In this study, serum potassium levels 
were >5.5 mmol/L in 12% of patients in the 
eplerenone group and 7% of those on pla-
cebo—a statistically significant difference. 
Eplerenone therapy was reduced or discon-
tinued in hyperkalemic patients. No one suf-
fered from the significant, but rare, sequelae 
associated with hyperkalemia, including ar-
rhythmias and sudden death. 
it makes  
sense to use  
spironolactone,  
another  
mineralocorticoid- 
receptor  
antagonist, as 
a first-line drug 
and reserve 
eplerenone  
for patients who 
can’t tolerate it.
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Only 2.4% of the patients included in this 
study were African American (the majority 
were white, but there was a significant number 
[11.5%] of Asians). We cannot be sure that Af-
rican Americans with less severe heart failure 
would reap the same benefits from treatment 
with a mineralocorticoid-receptor antagonist.
This was a well-done RCT, which found a 
significant benefit of eplerenone over placebo. 
It was a relatively small study, however, and it 
would help if the findings were replicated in 
larger studies. It is noteworthy, too, that this 
study was supported by Pfizer, which manu-
factures eplerenone, and 2 of the authors were 
employed by the pharmaceutical company.
CHALLENGES TO IMPLEMENTATION
close follow-up, lab work is crucial
Hyperkalemia can be a significant side effect 
of both spironolactone and eplerenone. Pa-
tients started on either medication will need 
close follow-up and frequent lab monitoring 
of potassium levels. Patients who are unable 
or unwilling to comply with this strict follow-
up are not good candidates for either drug. 
Overall, this is a straightforward change 
to implement. In many cases, convincing pa-
tients of the benefits of taking yet another pill 
will be the greatest challenge. For the right pa-
tient population, however, both eplerenone 
and spironolactone appear to be medications 
we should encourage more often.               JFP
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